Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03382015 · ClinicalTrials.gov registry record · NA
Effect of BKR-013 on Average Daily Glucose Levels
A NA study, sponsored by BioKier.
- Completed
- Registry status
- NA
- Development phase
- 14
- Enrollment target
NCT03382015: Completed NA study, sponsored by BioKier.
NCT03382015 is a NA study that has completed, run by BioKier. The registered enrollment target is 14 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03382015, a NA study, has completed, sponsored by BioKier.
- COMPLETED
- Registry status
- NA
- Development phase
- 14 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the effect of BKR-013 on average daily glucose (ADG) levels in type 2 diabetes (T2D) subjects during 28 days of either placebo or active test product administration. Subjects will serve as their own controls in this crossover design, and ADG will be compared while a subject is on active test product versus while they received placebo test product.
Primary Outcome
Intra-patient comparison of ADG in Part 1 vs Part 2
Interventions
- OTHER BKR-013 or Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2018-01-09 |
| Est. Completion | 2018-06-30 |
| Phase | NA |
What the finished NCT03382015 record still lists
NCT03382015 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 1 intervention - of which BKR-013 or Placebo is the first listed.
NCT03382015 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03382015 about?
NCT03382015 is a clinical study titled "Effect of BKR-013 on Average Daily Glucose Levels". The purpose of this study is to evaluate the effect of BKR-013 on average daily glucose (ADG) levels in type 2 diabetes (T2D) subjects during 28 days of either placebo or active test product administration. Subjects will serve as their own controls in this crossover design, and ADG will be compared ...
What is the current status of trial NCT03382015?
This trial is currently completed. It is a NA study. The enrollment target is 14 participants. The study started on 2018-01-09. Estimated completion is 2018-06-30.
What interventions are being tested in trial NCT03382015?
The interventions under investigation include: BKR-013 or Placebo (OTHER).
Who is sponsoring clinical trial NCT03382015?
This trial is sponsored by BioKier, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03382015's enrollment target sits among peer trials
14 1909th of 2000 higher than 90 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy